< 1 minute read
Sep. 15, 2021
GNF2133: An oral in vivo GSK3-beta-sparing DYRK1A kinase inhibitor
GNF2133
GSK3β-sparing DYRK1A kinase inhibitor orally efficacious in proliferation model, but non-specific proliferation observed from cellular phenotypic screen and opt. J. Med. Chem. Feb. 20, 2020 Novartis (GNF), San Diego, CA